Biostate AI and Weill Cornell Medicine Develop AI for Leukemia Care
Biostate AI and Weill Cornell Medicine have announced a strategic collaboration to develop artificial intelligence models aimed at personalizing leukemia care, as stated in a press release. The partnership will initially focus on acute myeloid leukemia (AML), utilizing Weill Cornell's extensive biorepository of bone marrow and blood samples.
Biostate AI will employ its proprietary barcode-integrated reverse transcription (BIRT) technology for RNA sequencing to analyze RNA expression from patient samples. This data will be used to pre-train and fine-tune a transformer-based AI model, which will assist in AML subtype stratification, disease prognosis, and therapy selection.
The collaboration will begin with a pilot phase involving 1,000 retrospective samples, with plans to expand to 50,000 samples upon achieving certain technical milestones. This effort aims to enhance the precision of treatment decisions, potentially improving patient outcomes by tailoring therapies such as bone marrow transplants and BCL-2 inhibitors.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 20 IDC Names ZS a Leader in Life Sciences Evidence Services Sep 20 Brainomix Selected for UK Future Fifty Programme Sep 19 Rutgers and RWJBarnabas Health Launch AWS Health Innovation Hub Sep 19 Vetology Rebuilds 94 Veterinary Radiology AI Classifiers Sep 19 NAVER D2SF Backs ImpriMed in $10 Million Bridge RoundLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
HealthIQ Solutions and Eirion.ai Partner on Predictive AI for Remote Care
MediSights Reports Study Using AI Agents for Myeloma Market Research
ADLM Calls for CLIA Rules to Cover AI in Laboratory Medicine
BreakBio Plans Clinic Entry for Personalized Cancer Drugs
Atman Health Wins ARPA-H Award to Build Heart Failure AI
Daily AI Brief: the AI news that matters, in your inbox.